Current Medicinal Chemistry

ISSN: 0929-8673




Current Medicinal Chemistry
Volume 17, Number 15, 2010


Contents

Tyrosyl-DNA Phosphodiesterase 1 Targeting for Modulation of Camptothecin-Based Treatment Pp. 1500-1508
G. L. Beretta, G. Cossa, L. Gatti, F. Zunino and P. Perego
[Abstract] [Purchase Article] [PMID: 20166932 PubMed - indexed for MEDLINE]


Recent Advances in Anti-Survivin Treatments for Cancer Pp. 1509-1515
R.K. Kanwar, C.H.A. Cheung, J.-Y. Chang and J.R. Kanwar
[Abstract] [Purchase Article] [PMID: 20166933 PubMed - indexed for MEDLINE]


Drug Design Studies of the Novel Antitumor Targets Carbonic Anhydrase IX and XII Pp. 1516-1526
O. Ozensoy Guler, G. De Simone and C.T. Supuran
[Abstract] [Purchase Article] [PMID: 20166929 PubMed - indexed for MEDLINE]


Editor’s Choice
Potential and Perspectives of Cyclonucleosides Pp. 1527-1549
A. Mieczkowski and L.A. Agrofoglio
[Abstract] [Purchase Article] [PMID: 20166935 PubMed - indexed for MEDLINE]


In Silico Prediction of Binding Sites on Proteins Pp. 1550-1562
Simon Leis, Sebastian Schneider and Martin Zacharias
[Abstract] [Purchase Article] [PMID: 20166931 PubMed - indexed for MEDLINE]


Progress in COX-2 Inhibitors: A Journey So Far Pp. 1563-1593
Asit K. Chakraborti, Sanjeev K. Garg, Raj Kumar, Hashim F. Motiwala and Pradeep S. Jadhavar
[Abstract] [Purchase Article] [PMID: 20166930 PubMed - indexed for MEDLINE]


Trypanosomatid Parasites Causing Neglected Diseases Pp. 1594-1617
K. Nussbaum, J. Honek, C.M.C.v.C. Cadmus and T. Efferth
[Abstract] [Purchase Article] [PMID: 20166934 PubMed - indexed for MEDLINE]



Abstracts


[Back to top] [Purchase Article] [PMID: 20166932 PubMed - indexed for MEDLINE]
Tyrosyl-DNA Phosphodiesterase 1 Targeting for Modulation of Camptothecin-Based Treatment
G. L. Beretta, G. Cossa, L. Gatti, F. Zunino and P. Perego

The targeting of specific DNA repair mechanisms may be a promising strategy to improve the efficacy of antitumor therapy. The cytotoxic effects of the clinically relevant topoisomerase 1 (Top1) poison camptothecins are related to the generation of DNA lesions and tumor cells may be resistant to DNA damaging agents due to increased repair. Tyrosyl-DNA phosphodiesterase 1 (TDP1) is implicated in the repair of strand breaks by removing abortive Top1/DNA complexes. Thus, a role for TDP1 in counteracting DNA damage induced by camptothecins has been proposed. Here, we review the role of TDP1 in DNA repair with particular reference to TDP1 function, its cooperation with other pathways and the development of pharmacological inhibitors.


[Back to top] [Purchase Article] [PMID: 20166933 PubMed - indexed for MEDLINE]
Recent Advances in Anti-Survivin Treatments for Cancer
R.K. Kanwar, C.H.A. Cheung, J.-Y. Chang and J.R. Kanwar

Apoptosis occurs via extrinsic or intrinsic signalling each triggered and regulated by many different molecular pathways. In recent years, the selective induction of apoptosis through survivin in tumour cells has been increasingly recognized as a promising approach for cancer therapy. Survivin has multiple functions including cytoprotection, inhibition of cell death, and cell-cycle regulation, especially at the mitotic process stage, all of which favour cancer survival. Many studies on clinical specimens have shown that survivin over expression is invariably up regulated in human cancers, associated with resistance to chemotherapy or radiation therapy, and linked to poor prognosis, suggesting that cancer cells survive with survivin. On the basis of these findings, survivin has been proposed as an attractive target for new anticancer interventions. Survivin inhibitors recently entered clinical trials. Recent studies suggest a possible role for survivin in regulating the function of normal adult cells. However, the expression and function of survivin in normal tissues are still not well characterized and understood. Still better understandings of survivin’s role in tumour versus normal cells are needed for designing the strategies to selectively disrupt survivin in cancers. In the present review, we summarise the importance of recent survivin-targeted cancer therapy for future clinical application.


[Back to top] [Purchase Article] [PMID: 20166929 PubMed - indexed for MEDLINE]
Drug Design Studies of the Novel Antitumor Targets Carbonic Anhydrase IX and XII
O. Ozensoy Guler, G. De Simone and C.T. Supuran

The carbonic anhydrase (CA, EC 4.2.1.1) isozymes IX and XII are predominantly found in tumor cells and show a restricted expression in normal tissues. By efficiently hydrating carbon dioxide to protons and bicarbonate, these CAs contribute significantly to the extracellular acidification of solid tumors. CA IX and XII are overexpressed in many such tumors in response to the hypoxia inducible factor (HIF) pathway, and research on the involvement of these isozymes in cancer has progressed in recent years. The report of the X-ray crystal structure of CA IX, which is a dimeric protein with a quaternary structure not evidenced earlier for this family of enzymes, allows for structure-based drug design campaigns of inhibitors against this novel antitumor target. Indeed, it has been known for some time that aromatic/heterocyclic sulfonamides and sulfamates have good affinity for this isoform, but generally they do not show specificity for the inhibition of the tumor-associated isoform versus the remaining CA isozymes (CA I-VII, and XII-XV) found in mammals. Recently, we reported several classes of compounds with good selectivity for the tumor-associated CAs, being shown that CA IX/XII inhibition reverses the effect of tumor acidification, leading to inhibition of the cancer cells growth. CA IX/XII are now proposed as novel therapeutic antitumor targets. Furthermore, as some types of CA inhibitors (CAIs), such as the fluorescent sulfonamides accumulate only in hypoxic tumor cells overexpressing these enzymes, CAIs may be also used as diagnostic tools for imaging of hypoxic cancer cells. Work from several laboratories recently reported the proof-of-concept studies for the use of CA IX/XII inhibitors as well as antibodies both in the therapy and imaging of hypoxic tumors.


[Back to top] [Purchase Article] [PMID: 20166935 PubMed - indexed for MEDLINE]
Potential and Perspectives of Cyclonucleosides
A. Mieczkowski and L.A. Agrofoglio

Cyclonucleosides are defined as analogs of natural nucleosides with an additional covalent bond between the nucleobase and the sugar moiety. They differ from classical nucleosides in more rigid structure and fixed conformation, which are responsible for unique properties and further applications. For instance, rigid structure can determine better interaction of the molecule with the acceptor, which is important in the design new bioactive of compounds. This class of nucleosides is known from the early fifties, when Todd et al. obtained cyclic salts of nucleosides. Although the formation of cyclic salts by purine nucleosides is quite common, the variety of cyclonucleosides is not only limited to this group. Up to now, various miscellaneous purine and pyrimidine cyclonucleosides and their analogs with great structural diversity were obtained; they differ from each other in position, length and type of linkage. Purine cyclonucleosides form a large group of artificially obtained derivatives. However, recently turned out cyclonucleosides also exist in nature. In fact, cyclopurine N³,5-cycloxanthine was isolated from a marine sponge of genus Eryus sp. The aim of this review is to give an overview of the synthesis of some cyclonucleosides according to their structural types and to underline their biological activities. The article also refers to other relevant review articles that have covered particular areas of investigation or have dealt in depth with a single compound.


[Back to top] [Purchase Article] [PMID: 20166931 PubMed - indexed for MEDLINE]
In Silico Prediction of Binding Sites on Proteins
Simon Leis, Sebastian Schneider and Martin Zacharias

The majority of biological processes involve the association of proteins or binding of other ligands to proteins. The accurate prediction of putative binding sites on the protein surface can be very helpful for rational drug design on target proteins of medical relevance, for predicting the geometry of protein-protein as well as protein-ligand complexes and for evaluating the tendency of proteins to aggregate or oligomerize. A variety of computational methods to rapidly predict protein-protein binding interfaces or binding sites for small drug-like molecules have been developed in recent years. The principles of methods available for protein interface and pocket detection are summarized, including approaches based on sequence conservation, as well as geometric and physicochemical surface properties. The performance of several Web-accessible methods for ligand binding site prediction has been compared using protein structures in bound and unbound conformation and homology modeled proteins. All methods tested gave very promising predictions even on unbound and homology modeled protein structures, thus indicating that current methods are robust in relation to modest conformational changes associated with the ligand binding process.


[Back to top] [Purchase Article] [PMID: 20166930 PubMed - indexed for MEDLINE]
Progress in COX-2 Inhibitors: A Journey So Far
Asit K. Chakraborti, Sanjeev K. Garg, Raj Kumar, Hashim F. Motiwala and Pradeep S. Jadhavar

The non-steroidal anti-inflammatory drugs (NSAIDs) are diverse group of compounds used for the treatment of inflammation, since the introduction of acetylsalicylic acid in 1899. Traditional (first generation) NSAIDs exert anti-inflammatory, analgesic, and antipyretic effects through the blockade of prostaglandin synthesis via non-selective inhibition of cyclooxygenase (COX-1 and COX-2) isozymes. Their use is associated with side effects such as gastrointestinal and renal toxicity. A number of selective (second generation) COX-2 inhibitors (rofecoxib, celecoxib, valdecoxib etc.) were developed as safer NSAIDs with improved gastric safety profile. Observation of increased cardiovascular risks in APPROVe (Adenomatous Polyp Prevention on Vioxx) study sent tremors and led to voluntary withdrawn of Vioxx (rofecoxib) by Merck from the market in September 2004 followed by Bextra (valdecoxib) in 2005 raising a question on the safety of selective COX-2 inhibitors. This leads to the belief that these effects are mechanism based and may be class effect. However, some studies suggested association of traditional NSAIDs with similar effects requiring a relook into the whole class of NSAIDs rather than simply victimizing the selective COX-2 inhibitors. Recognition of new avenues for selective COX-2 inhibitors such as cancer, Alzheimer’s disease, Parkinson’s disease, schizophrenia, major depression, ischemic brain injury and diabetic peripheral nephropathy has kindled the interest in these compounds. This review highlights the various structural classes of selective COX-2 inhibitors developed during past seven years (2003-2009) with special emphasis on diaryl-hetero/carbo-cyclic class of compounds. Molecular modeling aspects are also briefly discussed.


[Back to top] [Purchase Article] [PMID: 20166934 PubMed - indexed for MEDLINE]
Trypanosomatid Parasites Causing Neglected Diseases
K. Nussbaum, J. Honek, C.M.C.v.C. Cadmus and T. Efferth

Parasitic diseases such as Kala azar (visceral leishmaniasis), Chagas disease (American trypanosomiasis) and African sleeping sickness (human African trypanosomiasis) are affecting more than 27 million people worldwide. They are categorized amongst the most important neglected diseases causing approximately 150,000 deaths annually. As no vaccination is available, treatment is solely dependent on chemotherapeutic drugs. This review provides a comprehensive insight into the treatment of Kala azar, Chagas disease and African sleeping sickness. In addition to established drugs, novel small-molecule-based therapeutic approaches are discussed.

Drugs currently used for the treatment of Kala azar include pentavalent antimonials, Amphotericin B, Miltefosine, and Paromomycin. Liposomal formulations such as AmBisome^® provide promising alternatives. Furthermore, antiproliferative compounds might open new avenues in Kala azar treatment.

Regarding Chagas disease, chemotherapy is based on two drugs, Nifurtimox and Benznidazole. However, sequencing of T. cruzi genome in the year 2005 raises a hope for new drug targets. Proteases, sterols and sialic acids are potential promising drug targets.

Suramin, Pentamidine, Melarsoprol and Eflornithine are well-established drugs to treat African sleeping sickness. New treatment options include combination therapy of Eflornithine and Nifurtimox, a Chagas disease therapeutic.

However, all approved chemotherapeutic compounds for trypanosomatid diseases suffer from high toxicity. Further, increasing resistance limits their efficacy and compliance.